FDA Reasserts End to Tirzepatide Shortage, Impacting Compounding Pharmacies and Telehealth Platforms
FDA ends tirzepatide shortage, impacting compounding pharmacies and telehealth platforms. This decision reinstates Lilly’s patent enforcements, halting production of compounded tirzepatide and potentially impacting patient access.